© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Andrea Stallings, PA
Articles
Impact of Delayed Intervention In Stage 2 Type 1 Diabetes
December 23, 2024
Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.
Defining the Stages of Type 1 Diabetes
December 23, 2024
Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.
Guidelines for Type 1 Diabetes Screening
December 23, 2024
Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.
Assessing the Burden of Type 1 Diabetes
December 19, 2024
Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.
Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management
June 11, 2024
The panel of experts from UCSD concludes the discussion on delaying the onset of stage 3 T1D by providing key takeaways and clinical advice on the treatment of patients with this condition.
Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement
June 11, 2024
Focusing on the utilization of teplizumab, the expert panel from UCSD shares insights in how to select patients for this treatment and provide practical tips for the infusion process, and infusion location options.
Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights
June 11, 2024
The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.
Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact
June 11, 2024
Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.
Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities
June 11, 2024
Schafer Boeder, MD and Andrea Stallings, PA delve into the intricacies of autoantibody screening tests for T1D with detailed insights on their methodologies, interpretation nuances, and practical analysis considerations.
Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening
June 11, 2024
Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.